The United States has removed tariffs on select specialty drugs imported from India, providing relief to Indian pharmaceutical exporters supplying these products to the US market.
The tariff waiver covers specific specialty pharmaceutical products and is expected to improve the competitiveness of eligible Indian drug exports by reducing the additional costs associated with US imports.
The move is significant for India’s pharmaceutical industry, which has a strong presence in the US market, particularly in generic and specialty medicines. Indian drugmakers have been seeking greater clarity on the impact of US trade measures and tariff changes on pharmaceutical shipments.
The removal of tariffs for the specified products could support export volumes and help Indian manufacturers maintain their position in the US market. However, the benefit will depend on the products covered by the exemption and the duration and conditions attached to the tariff relief.
The development comes as India and the US continue to engage on trade and market-access issues across several sectors. Pharmaceutical exports remain an important component of India’s merchandise trade with the US, making tariff-related developments closely watched by the industry.
Exporters are expected to assess the eligible product categories and determine the impact of the tariff waiver on pricing, supply chains and future shipments to the US.